Covered recipient · General Payments record
CHANH HUYNH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$21,511.59
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $17,907.50 | 10 |
| Honoraria | $1,550.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,400.00 | 1 |
| Food and Beverage | $617.94 | 35 |
| Education | $36.15 | 4 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,664.64 | 5 |
| Lilly USA, LLC | $2,709.78 | 3 |
| Janssen Scientific Affairs, LLC | $2,031.62 | 2 |
| Janssen Biotech, Inc. | $2,011.39 | 5 |
| Celgene Corporation | $1,699.11 | 4 |
| BeiGene USA, Inc. | $1,650.00 | 1 |
| Karyopharm Therapeutics Inc. | $1,629.98 | 8 |
| Immunomedics, Inc. | $1,400.00 | 1 |
| Incyte Corporation | $1,347.95 | 7 |
| Puma Biotechnology, Inc. | $1,000.00 | 1 |
| Epizyme, Inc., | $147.07 | 2 |
| McKesson Specialty Care Distribution, LLC | $70.00 | 1 |
| AbbVie Inc. | $36.43 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $24.00 | 1 |
| Stemline Therapeutics Inc. | $19.57 | 1 |
| Janssen Pharmaceuticals, Inc | $17.45 | 2 |
| Octapharma USA, Inc. | $17.25 | 1 |
| GENZYME CORPORATION | $12.45 | 1 |
| Global Blood Therapeutics, Inc. | $11.79 | 1 |
| Aurobindo Pharma USA, Inc. | $11.11 | 1 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHANH HUYNH
NPI 1134324536 · CMS profile ID 50894
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
YORK, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134324536?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHANH HUYNH, NPI 1134324536, CMS profile ID 50894. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134324536?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). CHANH HUYNH, NPI 1134324536, CMS profile ID 50894. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134324536?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- CHANH HUYNH, NPI 1134324536, CMS profile ID 50894, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1134324536?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $21,511.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $8.09 | 01/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727824961 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $521,654.97 | 29 |
| PY2024 | Principal investigator | $517,579.87 | 27 |
| PY2023 | Principal investigator | $231,741.49 | 30 |
| PY2022 | Principal investigator | $82,932.77 | 64 |
| PY2021 | Principal investigator | $51,537.30 | 10 |
| PY2020 | Recipient | $1,425.00 | 1 |
| PY2020 | Principal investigator | $87,766.32 | 8 |
| PY2019 | Recipient | $4,725.00 | 1 |
| PY2019 | Principal investigator | $54,711.95 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
29 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,171.13 | 12/04/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202528526 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,636.28 | 10/29/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185546725 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 10/10/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336811 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,013.00 | 09/30/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190333150 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,466.74 | 08/27/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185546733 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 07/23/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336955 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,944.00 | 07/22/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328623 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $119,451.77 | 07/11/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK, INC | a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 | No dispute reported | 06/30/2026 | 1185546729 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $8,455.00 | 07/07/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328573 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/10/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337046 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,838.11 | 05/30/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185546731 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,944.00 | 05/20/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190331229 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $13,155.00 | 05/12/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190338850 |
| Principal investigator 1 | AstraZeneca UK Limited | $115.70 | 04/30/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK, INC | A multi center,multi country prospective observational study of patients initiating T DXd in the first or second treatment line for HER2 unresectable and or metastatic breast cancer | No dispute reported | 06/30/2026 | 1185546737 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,107.00 | 04/29/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190338855 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/15/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321942 |
| Principal investigator 1 | Celgene Corporation | $4,750.00 | 03/26/2025 | Non-covered Recipient Entity Oncare Alliance, Llc | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222306437 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $6,338.00 | 03/25/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190331227 |
| Principal investigator 1 | Eli Lilly and Company | $3,175.00 | 03/11/2025 | Non-covered Recipient Entity WELLSPAN HEALTH | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187891796 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,584.01 | 02/24/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD | No dispute reported | 06/30/2026 | 1185546735 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 02/18/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325238 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 02/18/2025 | Non-covered Recipient Entity Cancer Care Associates of York | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325240 |
| Principal investigator 1 | Eli Lilly and Company | $265.90 | 02/10/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK, INC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187876579 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,074.85 | 01/29/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185546739 |
| Principal investigator 1 | BeiGene USA, Inc. | $13,089.00 | 01/28/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320338 |
| Principal investigator 1 | BeiGene USA, Inc. | $3,849.00 | 01/28/2025 | Non-covered Recipient Entity Cancer Care Associates of York, Inc. | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322342 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,479.00 | 01/24/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK, INC | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185546723 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,500.00 | 01/22/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185546727 |
| Principal investigator 1 | Eli Lilly and Company | $75,439.76 | 01/22/2025 | Non-covered Recipient Entity CANCER CARE ASSOCIATES OF YORK, INC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187875429 |